source
- FDA approves Rasonque, first-in-class RAS inhibitor for metastatic pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a RAS inhibitor, for the treatment of metastatic pancreatic adenocarcinoma. Rasonque is a tablet taken once daily that t…
- FDA greenlights Revolution Medicines' pancreatic cancer gamechangerFollowing dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for…Fierce Biotech · 9h ago↗ source